Shilajit for Health & Longevity

Evidence Review created on 05/09/2026 using AI4L / Opus 4.7

Also known as: Mumijo, Mumie, Moomiyo, Mineral Pitch, Salajit, Shilajatu, Asphaltum

Motivation

Shilajit is a tar-like, resinous exudate that seeps from rocks in high-altitude mountain ranges, most notably the Himalayas, Altai, and Caucasus. It is a complex mixture of plant-derived organic matter, predominantly fulvic and humic acids, along with several plant-derived bioactive compounds and trace minerals. Used for over three thousand years in Ayurvedic medicine, it has long been classified as a “rasayana” — a substance reputed to promote vitality and slow aging.

Modern scientific interest dates to mid-twentieth-century research in the Soviet Union and India, where the substance was studied for athletic performance and reproductive health. Small contemporary trials in aging adults have focused chiefly on testosterone support and exercise endurance, with a smaller body of work in postmenopausal bone density. Quality and authenticity vary widely across commercial products, and documented concerns over heavy-metal contamination in raw, unpurified material remain a central consideration for anyone evaluating shilajit today.

This review examines the available human and preclinical evidence for shilajit, its proposed mechanisms, expected benefits and risks, and the practical considerations relevant to those evaluating it as a longevity-oriented supplement.

Benefits - Risks - Protocol - Conclusion

Grokipedia

Shilajit

The Grokipedia entry compiles botanical, geological, and chemical background on shilajit alongside a summary of clinical and preclinical findings, providing a broad reference complement to this review.

Examine

Shilajit

The Examine page provides a structured, evidence-graded review of shilajit’s human research across testosterone, fertility, exercise, bone, and cognition, with direct links to the underlying trials.

ConsumerLab

Best Shilajit Supplements Review & Top Picks

The ConsumerLab review tests popular shilajit supplements for fulvic acid content and heavy-metal contamination (lead, arsenic, mercury, cadmium), reports on detected toxins such as thallium, and identifies a Top Pick — directly relevant to the sourcing-and-quality concerns central to evaluating any shilajit product.

Systematic Reviews

The following PubMed-indexed systematic reviews inform the evidence base for shilajit.

Do “testosterone boosters” really increase serum total testosterone? A systematic review - Morgado et al., 2024

A systematic review of 52 studies covering 27 proposed testosterone boosters, including a dedicated assessment of purified shilajit extract (PrimaVie). The authors conclude that purified shilajit can be considered possibly effective for men with late-onset hypogonadism (low testosterone production developing in older age), while most other tested compounds failed to raise total testosterone.
Pre-clinical Evaluation of Shilajit in Cancer: A Systematic Review - Das et al., 2026

A systematic review of preclinical evidence on shilajit’s anticancer activity, summarizing nine studies (eight in vitro and one in vivo osteosarcoma model). The authors report dose-dependent cytotoxicity, NF-κB (nuclear factor kappa-B, a master pro-inflammatory transcription factor that also drives cancer cell survival) pathway inhibition, and selectivity against cancer cells, while emphasizing that no qualifying clinical studies exist and clinical translation remains speculative.

Mechanism of Action

Shilajit’s biological activity is attributed to its complex mixture of organic and inorganic constituents rather than to a single active compound. The two best-characterized fractions are fulvic acid (a low-molecular-weight humic substance) and dibenzo-alpha-pyrones (DBPs), with smaller contributions from amino acids, eldagic acid derivatives, and trace minerals.

Mitochondrial bioenergetics: DBPs and fulvic acid appear to act as electron carriers and CoQ10 (coenzyme Q10, an antioxidant electron carrier in the mitochondrial electron transport chain) stabilizers, supporting the electron transport chain. Preclinical work suggests improved ATP (adenosine triphosphate, the cell’s primary energy currency) production and reduced lactate accumulation under exertion.
Antioxidant activity: Fulvic acid scavenges reactive oxygen species (ROS, unstable oxygen-containing molecules that damage cells) and upregulates endogenous antioxidant enzymes including superoxide dismutase and glutathione peroxidase.
Mineral and micronutrient transport: Fulvic acid chelates and ferries minerals across cell membranes, potentially enhancing the bioavailability of trace elements such as magnesium, zinc, and iron.
Endocrine modulation: Animal studies and small human trials suggest shilajit supports endogenous testosterone production, possibly via reduced oxidative stress in Leydig cells (the testosterone-producing cells of the testes) and modulation of the hypothalamic-pituitary-gonadal (HPG) axis.
Anti-inflammatory and anti-glycation effects: Fulvic acid has been shown to inhibit pro-inflammatory cytokines such as tumor necrosis factor alpha (TNF-α) and may reduce the formation of advanced glycation end-products (AGEs, sugar-modified proteins implicated in aging).
Neuroprotection: DBPs inhibit acetylcholinesterase (the enzyme that breaks down the neurotransmitter acetylcholine) and reduce tau aggregation in preclinical models of Alzheimer’s disease.

Competing perspectives exist: skeptical reviewers argue that much of shilajit’s reputed benefit reflects the placebo response and small-trial effects rather than a robust mechanistic signal, and that variability in product composition makes mechanism-to-clinical translation unreliable.

Shilajit is not a single pharmacological compound, so half-life, selectivity, tissue distribution, and CYP (cytochrome P450, the main family of liver enzymes that metabolize drugs) metabolism are not well defined for the whole resin. Fulvic acid is partially absorbed orally, with limited human pharmacokinetic data; DBPs appear to undergo hepatic metabolism but their primary CYP pathways remain poorly characterized.

Historical Context & Evolution

Shilajit has been used in traditional medicine for an estimated three thousand years, most prominently within the Ayurvedic system of India, where it is classified as a rasayana (rejuvenative) and considered one of the most important substances in the materia medica. It is mentioned in the Charaka Samhita and Sushruta Samhita as a treatment for general debility, urinary disorders, and reproductive concerns. Parallel traditions exist in the form of mumijo (Russia, Central Asia) and moomiyo (Mongolia), where it has been used for fracture healing, stamina, and recovery.

Modern scientific interest dates to mid-twentieth-century work in the Soviet Union, where mumijo was studied for athletic performance and wound healing. Indian pharmacological research from the 1970s onward, particularly by Shibnath Ghosal and colleagues, characterized fulvic acid and dibenzo-alpha-pyrones as principal bioactive constituents. This work led to small clinical trials in the 2000s and 2010s focused on male fertility, testosterone, and chronic fatigue.

Findings have evolved alongside skepticism. Early reports of broad rejuvenative effects gave way to more measured appraisals: meta-analyses and systematic reviews acknowledge consistent signals in male reproductive endpoints and exercise fatigue but flag small sample sizes, heterogeneous products, and frequent industry sponsorship. Concerns about heavy-metal contamination in unpurified material — raised by analytical chemists in the 1990s — drove the development of purified, standardized extracts (e.g., PrimaVie). The current picture is neither a clear vindication nor a clear dismissal of traditional claims.

Expected Benefits

A dedicated search was performed across PubMed, the Examine evidence database, systematic reviews, and clinical-trial registries to enumerate shilajit’s reported benefits.

Medium 🟩 🟩

Increased Total and Free Testosterone in Adult Men

A purified shilajit extract was associated with increases in total and free testosterone in healthy adult males in a 90-day randomized, double-blind, placebo-controlled trial of 75 men (Pandit et al., 2016, funded by Natreon, the manufacturer of the PrimaVie extract used in the trial — a direct financial conflict of interest that recurs across most published shilajit RCTs). The proposed mechanism involves reduced oxidative stress in Leydig cells and HPG-axis modulation. The signal is consistent across two small RCTs (randomized controlled trials, the standard high-quality study design that compares an intervention against a placebo or alternative) and several open-label studies, but absolute increases are modest and product-specific.

Magnitude: Approximately 20% increase in total testosterone and 19% increase in free testosterone vs. placebo over 90 days at 250 mg twice daily of purified extract.

Improvements in Sperm Parameters in Subfertile Men

A purified shilajit extract improved sperm concentration, motility, and morphology in oligospermic men (men with low sperm count) (Biswas et al., 2010). Effects are attributed to antioxidant activity and reduced reactive oxygen species in seminal fluid. Replication beyond a small number of clinical sites is limited.

Magnitude: Approximately 60% increase in sperm count and 12–17% increase in total motility over 90 days at 100 mg twice daily of purified extract.

Low 🟩

Reduced Exercise-Induced Fatigue and Improved Time-to-Exhaustion

Shilajit supplementation modestly improved measures of muscle performance and reduced markers of exercise-induced muscle damage in small trials of recreationally active adults (Das et al., 2016). The proposed mechanism involves mitochondrial support, reduced lactate accumulation, and antioxidant protection. Effects are heterogeneous and dose-dependent.

Magnitude: Roughly 5–15% improvement in measures of muscular endurance and recovery markers; effect sizes vary substantially across trials.

Maintenance of Skeletal Muscle Strength During Training

A 250 mg/day or 500 mg/day shilajit protocol was associated with greater retention of maximal voluntary contraction strength compared to placebo in a small RCT of resistance-trained adults (Keller et al., 2019). Mechanism is thought to involve extracellular matrix and tendon collagen support.

Magnitude: Not quantified in available studies.

Improved Bone Mineral Density in Postmenopausal Women

A small RCT in postmenopausal women with osteopenia (mild loss of bone density that precedes osteoporosis) reported improvements in lumbar bone mineral density (BMD) and bone turnover markers after 48 weeks of purified shilajit (Pingali et al., 2022). Effects are attributed to mineral bioavailability and modulation of bone remodeling.

Magnitude: Approximately 1–2% increase in lumbar BMD over 48 weeks at 250 mg twice daily relative to placebo.

Adjunctive Glycemic Control ⚠️ Conflicted

Animal studies and a few small human studies report reductions in fasting glucose and improvements in insulin sensitivity with shilajit (Sharma et al., 2022). Other small human trials have shown no meaningful change. The mechanism may involve antioxidant protection of pancreatic beta cells and modest improvements in insulin signaling. Evidence is conflicted: animal data are more consistently positive than human data, and most human trials are short and small.

Magnitude: Reported reductions in fasting glucose of 5–10% in positive trials; null findings in others.

Speculative 🟨

Cognitive Support and Tau-Aggregation Inhibition

Preclinical work suggests fulvic acid and DBPs inhibit tau aggregation and acetylcholinesterase, with potential implications for Alzheimer’s disease and age-related cognitive decline (Carrasco-Gallardo et al., 2012). No adequately powered human trials in cognitively impaired populations have been published; the basis is mechanistic and animal data only.

General Adaptogenic and “Anti-Fatigue” Effect

Traditional and contemporary reports describe a non-specific increase in vitality and resilience to physical and psychological stressors. Mechanistic support is plausible (mitochondrial and antioxidant pathways), but the endpoint itself is poorly defined and lacks rigorous controlled human evidence beyond exercise-fatigue trials.

Iron Bioavailability for Mild Anemia

Animal and limited human work suggest shilajit may improve iron uptake and hemoglobin levels in mild iron-deficiency states, possibly via fulvic acid chelation and transport. Controlled human trials are very limited.

Benefit-Modifying Factors

Baseline testosterone status: Men with low-normal or low testosterone at baseline appear more likely to show measurable increases; men with mid-to-high baseline levels may see smaller or no change.
Sex differences: Most controlled trials of testosterone, fertility, and exercise endpoints have been conducted in men. Female-specific evidence is limited to bone-mineral-density data in postmenopausal women.
Age: Effects on muscle retention, bone density, and androgen support appear more pronounced in middle-aged and older adults than in young, healthy participants.
Pre-existing conditions: Subclinical hypogonadism, mild iron-deficiency anemia, osteopenia, and exercise-induced oxidative stress represent contexts where measurable benefits are more likely. In healthy young adults with no deficiency, signals are smaller.
Genetic polymorphisms: No well-validated pharmacogenomic markers for shilajit response exist. Variants influencing oxidative stress handling (e.g., GSTM1, SOD2 — genes encoding antioxidant enzymes) are biologically plausible modifiers but unstudied in this context.
Product purity and standardization: Effects observed with purified, standardized extracts (e.g., PrimaVie) cannot be assumed to transfer to raw, unpurified resin or low-grade powder, regardless of user characteristics.

Potential Risks & Side Effects

A dedicated search was performed using drug-reference sources (RxList, NIH supplement databases, Examine, drugs.com) and the published literature to enumerate shilajit’s reported risks and side effects.

High 🟥 🟥 🟥

Heavy-Metal and Mycotoxin Contamination from Unpurified Product

Raw, unprocessed shilajit can contain biologically significant amounts of arsenic, lead, mercury, and other heavy metals, as well as free radicals and mycotoxins. Long-term ingestion of contaminated material poses risks of cumulative toxicity affecting kidneys, neurological function, and the cardiovascular system. Evidence comes from analytical chemistry studies and independent product-testing reports. Purified, standardized extracts substantially mitigate but do not eliminate this risk.

Magnitude: Independent testing has documented heavy-metal levels exceeding regulatory limits in a meaningful share of unpurified products; specific failure rates vary by product and source.

Medium 🟥 🟥

Gastrointestinal Upset

Mild gastrointestinal symptoms — nausea, dyspepsia, transient changes in stool — have been reported across multiple clinical trials of shilajit. Symptoms are generally dose-related, resolve with discontinuation, and may be mitigated by taking the supplement with food.

Magnitude: Approximately 5–10% of participants in clinical trials report mild gastrointestinal symptoms; rates are similar to placebo in some studies.

Low 🟥

Allergic and Hypersensitivity Reactions

Rare cases of skin rash, itching, and hypersensitivity have been reported, presumably related to the heterogeneous botanical-derived content of shilajit. The mechanism is not well characterized, and reports come primarily from post-marketing observation.

Magnitude: Not quantified in available studies.

Increased Iron and Uric Acid Levels

Shilajit contains bioavailable iron and may modestly raise serum iron and ferritin, which is relevant for individuals with hemochromatosis or iron overload. Some reports describe small increases in uric acid, with potential implications for those predisposed to gout.

Magnitude: Not quantified in available studies.

Theoretical Risk of Hormonal Modulation in Hormone-Sensitive Conditions ⚠️ Conflicted

Because shilajit may modestly increase testosterone and possibly other androgens, individuals with prostate cancer, untreated benign prostatic hyperplasia, or hormone-sensitive malignancies have been advised to avoid use. The clinical signal in humans is small, and there are no controlled trials showing harm; the concern is primarily theoretical and mechanism-based.

Magnitude: Not quantified in available studies.

Speculative 🟨

Drug-Metabolism Alterations via Fulvic-Acid Effects on CYP Enzymes

Preclinical reports suggest fulvic acid and related humic substances may modulate cytochrome P450 enzymes, raising a theoretical risk of altered drug metabolism. No clinically relevant human interaction has been documented; the basis is in vitro and animal data only.

Long-Term Mineral Imbalance with Chronic High-Dose Use

Because shilajit contributes a complex mineral and trace-element load, chronic high-dose use could in principle disturb mineral homeostasis (e.g., iron, copper, manganese). No long-term controlled human data address this concern directly.

Risk-Modifying Factors

Pre-existing iron overload (e.g., hereditary hemochromatosis, untreated polycythemia): Shilajit’s iron content makes it inadvisable in conditions where iron should be minimized.
Hormone-sensitive cancers (e.g., prostate cancer, certain breast cancers): Theoretical androgen modulation argues for avoidance.
Pregnancy and lactation: Insufficient safety data; raw-product contamination concerns are particularly salient for fetal and infant exposure.
Renal impairment: Heavy-metal contamination concerns are amplified by reduced renal clearance; avoid unpurified products.
Sex differences: Most safety data come from male participants; female-specific safety in reproductive-age women is poorly characterized.
Age: Older adults with polypharmacy may face higher relative risk from undocumented drug-metabolism effects and from heavy-metal accumulation due to age-related declines in clearance.
Genetic polymorphisms: Variants in iron-handling genes (e.g., HFE — the gene mutated in hereditary hemochromatosis) and in heavy-metal detoxification pathways (e.g., GSTT1 — a gene encoding a glutathione-S-transferase enzyme involved in clearing toxins) plausibly modify risk but are not formally studied in shilajit users.
Baseline biomarkers: Elevated ferritin, elevated uric acid, or hormone-sensitive disease at baseline tilts the risk-benefit balance toward caution.

Key Interactions & Contraindications

Iron supplements (ferrous sulfate, ferrous fumarate, iron bisglycinate): Additive — combined use may produce excessive iron load, particularly in those with normal or high baseline ferritin. Severity: caution. Mitigation: avoid concurrent high-dose iron supplementation; check ferritin before stacking.
Anticoagulants and antiplatelets (warfarin, apixaban, rivaroxaban, aspirin, clopidogrel): Theoretical — fulvic acid may modulate platelet function or vitamin K status. Severity: monitor. Mitigation: monitor INR (international normalized ratio, a standardized blood test of clotting time) or relevant coagulation parameters when introducing shilajit alongside chronic anticoagulation.
Antihypertensives (ACE inhibitors — angiotensin-converting enzyme inhibitors that relax blood vessels, such as lisinopril; ARBs — angiotensin II receptor blockers that act on the same blood-pressure pathway, such as losartan; calcium channel blockers such as amlodipine): Possible — small reports suggest modest blood-pressure effects. Severity: monitor. Mitigation: track home blood pressure when initiating shilajit on top of antihypertensive therapy.
Diabetes medications (metformin, SGLT2 inhibitors — sodium-glucose co-transporter 2 inhibitors that lower glucose by promoting urinary glucose excretion, such as empagliflozin; sulfonylureas such as glipizide, insulin): Possible additive glycemic effect. Severity: monitor. Mitigation: track fasting glucose and continuous glucose monitoring trends; reduce hypoglycemic agent dose only under clinician supervision.
Hormone therapies (testosterone replacement, anastrozole, finasteride): Theoretical additive or interfering effect on androgens. Severity: caution. Mitigation: track total and free testosterone; avoid stacking without practitioner oversight.
Over-the-counter NSAIDs (non-steroidal anti-inflammatory drugs such as ibuprofen, naproxen): No direct documented interaction. Severity: low. Mitigation: standard NSAID-related cautions apply.
Supplement interactions — additive iron sources: Lactoferrin, multivitamins with iron, and food-based iron sources compound iron load.
Supplement interactions — additive testosterone-supportive supplements: Tongkat Ali (Eurycoma longifolia), fenugreek (Trigonella foenum-graecum), ashwagandha (Withania somnifera) — additive effects on androgen markers; severity: monitor.
Supplement interactions — additive antioxidants: High-dose antioxidant cocktails (vitamin C, vitamin E, N-acetylcysteine) may theoretically blunt some exercise adaptations; severity: monitor; mitigation: time around training as appropriate.
Populations to avoid:
- Hereditary hemochromatosis or untreated iron overload (ferritin >300 ng/mL in men, >200 ng/mL in women)
- Active or recent hormone-sensitive cancer (e.g., prostate cancer in active surveillance, hormone-receptor-positive breast cancer)
- Pregnancy and lactation
- Severe renal impairment (eGFR — estimated glomerular filtration rate, a measure of how well the kidneys filter blood — <30 mL/min/1.73m²)
- Active gout or hyperuricemia
- Children and adolescents (insufficient data)

Risk Mitigation Strategies

Use only purified, standardized extracts: To mitigate heavy-metal and mycotoxin contamination, restrict use to products that have been laboratory-purified (e.g., PrimaVie) and that publish certificates of analysis from accredited third-party labs (USP, NSF, ConsumerLab).
Verify heavy-metal testing thresholds: To mitigate cumulative heavy-metal toxicity, confirm products meet California Proposition 65 limits or stricter (lead <0.5 µg/day, arsenic <10 µg/day, mercury <0.3 µg/day, cadmium <4.1 µg/day).
Establish baseline labs: To mitigate iron overload, hormonal imbalance, and renal stress, obtain ferritin, total iron-binding capacity (TIBC), total and free testosterone, prostate-specific antigen (PSA, in men over 40), comprehensive metabolic panel (CMP, including kidney function), and uric acid before starting.
Start at the low end of the studied range: To mitigate gastrointestinal side effects and to allow tolerance assessment, begin at 250 mg/day of purified extract for 1–2 weeks before considering higher doses.
Take with food: To mitigate gastrointestinal symptoms, take shilajit with a meal rather than on an empty stomach.
Monitor at 8–12 weeks and every 6 months thereafter: To mitigate cumulative risks, recheck ferritin, hepatic function, kidney function, and relevant hormones; adjust or discontinue if biomarker drift is observed.
Cycle off periodically: To mitigate any cumulative mineral or heavy-metal load, plan for periodic discontinuation (e.g., 1 month off after 3–6 months on); see Discontinuation & Cycling.
Avoid stacking with iron-containing supplements without monitoring: To mitigate iron overload, treat shilajit as a partial iron source and reduce concurrent iron supplementation accordingly.
Stop and seek evaluation for new symptoms: Discontinue and seek clinical evaluation for unexplained fatigue, jaundice, peripheral neuropathy, or persistent gastrointestinal symptoms — possible signs of heavy-metal toxicity or hepatic stress.

Therapeutic Protocol

Standard purified-extract dose: 250–500 mg of a purified, standardized shilajit extract once or twice daily, with meals. The most-cited human RCT protocol uses 250 mg twice daily of PrimaVie for 8–12 weeks; this regimen was developed by the Natreon research group (Sanni Raju and colleagues) and adopted in the testosterone trials of Pandit and colleagues at Rangaraya Medical College and the bone-density trials of Pingali and Nutalapati at Nizam’s Institute of Medical Sciences.
Resin form: A pea-sized portion (approximately 300–500 mg) of authenticated, lab-tested resin once or twice daily, dissolved in warm water, milk, or tea. The resin form is the traditional Ayurvedic preparation popularized in the modern Western supplement market by suppliers such as Lotus Blooming Herbs (Bairo Putnam) and Pürblack.
Powder form: Generally less standardized than purified extracts; if used, follow manufacturer guidance and verify third-party testing.
Best time of day: Morning and/or early afternoon, ideally with a meal containing fat and protein to support absorption of fulvic acid and trace minerals. Late-evening dosing is not contraindicated but is less commonly used in trial protocols.
Half-life and dosing frequency: Pharmacokinetics of the whole resin are not well characterized; fulvic acid is partially absorbed orally with limited human pharmacokinetic data. Twice-daily dosing was used in the most-cited testosterone and fertility RCTs and is the most evidence-supported regimen for sustained effect.
Single vs. split dosing: Split dosing (twice daily) is the modal approach in trials demonstrating endocrine and exercise endpoints. Single morning dosing may be acceptable for general use at doses ≤500 mg.
Genetic polymorphisms: No validated pharmacogenomic dose adjustments exist. Carriers of HFE C282Y or H63D variants (associated with hereditary hemochromatosis) should generally avoid shilajit due to its iron content rather than adjust dose.
Sex-based differences: Most RCT dosing comes from male cohorts. For postmenopausal women evaluating shilajit for bone-density support, the published protocol is 250 mg twice daily for 48 weeks (Pingali et al., 2022).
Age-related considerations: Older adults (65+) may benefit from starting at 250 mg/day and titrating slowly given polypharmacy and reduced renal clearance.
Baseline biomarker thresholds: Initiation generally appropriate when ferritin <200 ng/mL (men) or <150 ng/mL (women), eGFR ≥60 mL/min/1.73m², and uric acid below the gout threshold.
Pre-existing health conditions: Avoid in active hormone-sensitive cancer, hereditary hemochromatosis, severe renal impairment, pregnancy, and lactation. Use with caution and monitoring in metabolic syndrome, type 2 diabetes (because of glycemic effect), and chronic kidney disease.

Discontinuation & Cycling

Lifelong vs. short-term: Shilajit is generally used in defined courses (8–12 weeks for endocrine and exercise endpoints; 24–48 weeks in bone-density trials) rather than lifelong continuous use. There is no evidence that indefinite continuous supplementation provides benefit beyond a periodic-use protocol.
Withdrawal effects: No physical dependence or withdrawal syndrome has been documented. Benefits gained during a course (e.g., increased testosterone) may regress toward baseline within weeks to months after discontinuation.
Tapering: Tapering is not required from a pharmacological standpoint; abrupt discontinuation has not been associated with rebound effects.
Cycling: A common pragmatic protocol is 3–6 months on, followed by 1–2 months off, to allow biomarker re-assessment and to limit any cumulative mineral or heavy-metal load. Cycling is supported more by precaution and traditional practice than by controlled human data showing efficacy advantages over continuous use.

Sourcing and Quality

Purified, standardized extracts: Choose products that disclose extraction and purification processes (e.g., PrimaVie by Natreon) and that standardize for fulvic acid (typically ≥50%) and dibenzo-alpha-pyrones.
Third-party testing: Look for certificates of analysis from independent laboratories (USP, NSF, ConsumerLab) that verify heavy-metal content (lead, arsenic, mercury, cadmium), microbial contamination, and label claims.
Form considerations: Purified extracts in capsules or tablets offer the most consistent dosing and the lowest contamination risk. Resin (paste/tar) is the traditional form but quality varies dramatically by source; bulk powders are the most variable category.
Geographic origin: Himalayan and Altai sources are most common; geographic origin alone does not guarantee quality. Authenticity testing (fulvic acid content, mineral profile) is more informative than country of origin.
Reputable products: Brands using PrimaVie include several mainstream supplement manufacturers (e.g., Pure Encapsulations, NOW Foods, Life Extension, Natreon’s own labeling). Cap-Beauty, Lotus Blooming Herbs, and Pürblack are commonly cited resin sources, though independent verification of any specific lot remains important.
Red flags: Avoid unbranded or generic resin sold without certificates of analysis, products with vague label claims (e.g., “high fulvic acid” without a percentage), and products with implausibly low prices for purported Himalayan resin.

Practical Considerations

Time to effect: Endocrine effects (testosterone, sperm parameters) typically require 8–12 weeks of consistent use before measurable change. Bone density effects require 24–48 weeks. Subjective energy or recovery effects, where present, may be reported within 2–4 weeks.
Common pitfalls: Buying unpurified or unverified resin, expecting rapid changes within days, stacking with multiple other testosterone-support supplements without baseline labs, and continuing indefinitely without periodic biomarker reassessment.
Regulatory status: In the United States, shilajit is sold as a dietary supplement under the Dietary Supplement Health and Education Act (DSHEA, the 1994 law that established the supplement regulatory framework). It is not approved as a drug for any indication. Quality oversight is therefore manufacturer-dependent rather than centrally enforced.
Cost and accessibility: Purified-extract capsules (PrimaVie) typically run $20–$50 per month at studied doses. Authentic resin is generally more expensive per gram but lasts longer. Counterfeit or contaminated products are widely available online at lower price points; cost differences of an order of magnitude often reflect quality.

Interaction with Foundational Habits

Sleep: Direction is generally neutral or mildly potentiating for restorative sleep. Mechanism is not well characterized; some users report improved sleep quality, possibly secondary to reduced exercise-induced inflammation. No robust data suggest sleep disruption. Practical consideration: late-evening dosing is uncommon in trial protocols; morning or early-afternoon dosing is preferred.
Nutrition: Direction is potentiating when taken with a meal containing fat and protein, which may enhance absorption of fulvic acid and trace minerals. Iron-rich diets compound shilajit’s iron contribution. Practical consideration: avoid concurrent high-dose iron supplementation; for individuals on plant-based diets with iron-binding compounds (phytates, oxalates), shilajit may modestly improve mineral absorption via fulvic-acid-mediated transport.
Exercise: Direction is generally potentiating for endurance and recovery endpoints in the small available trials. Mechanism is mitochondrial and antioxidant. Practical consideration: dosing 60–90 minutes pre-exercise has been used in fatigue trials; chronic daily dosing rather than acute pre-workout dosing is more consistent with the published evidence base. High-dose antioxidant stacks taken alongside training may theoretically blunt some hypertrophy adaptations, though this concern is not specific to shilajit.
Stress management: Direction is theoretically potentiating via traditional adaptogenic claims, with some preclinical support for hypothalamic-pituitary-adrenal (HPA) modulation. Human data on perceived stress and cortisol are limited. Practical consideration: shilajit is not a substitute for established stress-management practices; it is best considered a supplement to, not a replacement for, sleep, exercise, and nutrition optimization.

Monitoring Protocol & Defining Success

Baseline testing is recommended before initiating shilajit, focused on iron status, hormones, kidney function, and metabolic markers. The following table summarizes the core panel.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
Ferritin	50–150 ng/mL (men), 50–120 ng/mL (women)	Detect iron overload risk	Conventional reference ranges (up to 300+ ng/mL) tolerate higher values than functional medicine ranges. Best paired with TIBC and transferrin saturation.
Total iron-binding capacity (TIBC)	250–400 µg/dL	Contextualize iron status	Pair with ferritin; transferrin saturation = (serum iron / TIBC) × 100, target 20–45%.
Total testosterone	600–900 ng/dL (men); age-appropriate for women	Track endocrine effect	Draw in the morning (08:00–10:00); fasting preferred.
Free testosterone	9–25 pg/mL (men)	Track bioavailable androgen	Calculate free or use equilibrium dialysis; same morning timing.
PSA	<2.5 ng/mL (men over 40)	Screen before androgen-modulating supplementation	Prostate-specific antigen, a blood marker used to screen for prostate inflammation or cancer. Repeat at 3–6 months if shilajit is continued; rising PSA warrants evaluation.
Comprehensive metabolic panel (CMP)	Within reference, with eGFR ≥60 mL/min/1.73m²	Confirm baseline kidney and liver function	Fasting preferred; flags renal impairment that contraindicates use.
Uric acid	3.5–6.0 mg/dL (men), 2.5–5.5 mg/dL (women)	Identify gout risk	Conventional range tolerates higher values; functional range is tighter.
Hemoglobin/hematocrit	13.5–17.5 g/dL (men), 12.0–15.5 g/dL (women)	Detect erythrocytosis (excess red blood cells)	Relevant if shilajit’s iron contribution drives erythropoiesis.
High-sensitivity C-reactive protein (hs-CRP)	<1.0 mg/L	Track systemic inflammation	Optional but useful given antioxidant-mechanism claims.
Fasting glucose / HbA1c	<90 mg/dL / <5.4%	Track glycemic effect	HbA1c (glycated hemoglobin, a measure of average blood glucose over ~3 months). Especially relevant if combined with diabetes medications.

Ongoing monitoring cadence: recheck the relevant subset (ferritin, hormones if androgens are a target, CMP, uric acid) at 8–12 weeks after initiation, then every 6 months while continuing use.

Qualitative markers to track:

Subjective energy and stamina across the day
Exercise recovery time and perceived exertion at fixed workloads
Sleep quality and morning alertness
Cognitive clarity and focus
Libido and morning erections (men)
Skin and hair quality changes
Joint comfort during and after exercise

Emerging Research

Cardiometabolic and weight-loss trials: A randomized, double-blind, placebo-controlled trial in 112 sedentary adults with metabolic syndrome risk factors evaluated chromium, Phyllanthus emblica, and shilajit supplementation alongside an exercise and diet program (12-week intervention; primary endpoints flow-mediated dilation, fasting glucose, HbA1c, lipid panel) — see NCT06641596.
PrimaVie skeletal-muscle adaptation: A completed single-group study (N = 29) of purified shilajit extract (PrimaVie, 250 mg twice daily for 12 weeks, with treadmill training in the final 4 weeks) examined muscle gene expression and plasma biomarkers in pre-obese adults — see NCT02026414.
Bone density extension studies: Following the 48-week postmenopausal bone-density study by Pingali & Nutalapati, 2022, longer-duration trials are being designed to evaluate fracture-relevant endpoints such as femoral neck bone mineral density and bone turnover markers. Hyperlinked references for new published reports are not yet available.
Cognitive endpoints in mild cognitive impairment: Trials evaluating purified shilajit in mild cognitive impairment and early Alzheimer’s disease have been proposed based on the tau-aggregation work of Carrasco-Gallardo et al., 2012. Adequately powered human cognition trials remain limited.
Mitochondrial-function trials in chronic fatigue and long COVID: Mitochondrial bioenergetics is a plausible mechanistic target; small pilot studies in chronic fatigue and post-viral fatigue populations are emerging, though most remain unpublished or in early phases.
Heavy-metal and contamination surveillance: Independent product-testing organizations continue to publish updated heavy-metal screens. New analytical methods for distinguishing authentic shilajit from adulterated material are under development, including the chemistry framework reviewed by Kamgar et al., 2025.
Studies that could weaken the case: Larger placebo-controlled trials reproducing the testosterone signal at independent sites (without industry sponsorship) have not yet been completed; null results in such trials would substantially weaken the existing evidence. Long-term safety registries focused on heavy-metal accumulation are similarly absent and could shift the risk-benefit balance.
Studies that could strengthen the case: Mechanistic human trials with mitochondrial-function biomarkers (e.g., 31P-MRS phosphocreatine recovery), and randomized trials in postmenopausal bone health with fracture outcomes, would substantially strengthen the case if positive.

Conclusion

Shilajit is a complex resinous substance with a long traditional history and a small but coherent modern evidence base. The most consistently studied benefits — modest increases in testosterone and improvements in sperm parameters in men, retention of strength and modest improvements in exercise fatigue, and improved bone mineral density in postmenopausal women — rest on a handful of small randomized trials, often funded or sponsored by manufacturers of purified extracts. Mechanistic data point plausibly toward mitochondrial bioenergetics, antioxidant defense, and androgen-axis support, but the leap from mechanism to durable clinical benefit remains incompletely bridged.

The most important practical issue is product quality. Heavy-metal contamination in unpurified material is well documented and not a minor concern. Standardized, third-party-tested extracts substantially reduce this risk and align with the products used in published trials.

For the longevity-oriented adult, shilajit sits in a category where biological plausibility, traditional use, and limited modern evidence converge on a modest, conditional signal — strongest in older men, postmenopausal women with low bone density, and those with documented oxidative or fatigue burden — and where product variability and contamination risk are themselves substantive parts of the evidence picture.

Top - Benefits - Risks - Protocol

Shilajit for Health & Longevity

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

Medium 🟩 🟩

Increased Total and Free Testosterone in Adult Men

Improvements in Sperm Parameters in Subfertile Men

Low 🟩

Reduced Exercise-Induced Fatigue and Improved Time-to-Exhaustion

Maintenance of Skeletal Muscle Strength During Training

Improved Bone Mineral Density in Postmenopausal Women

Adjunctive Glycemic Control ⚠️ Conflicted

Speculative 🟨

Cognitive Support and Tau-Aggregation Inhibition

General Adaptogenic and “Anti-Fatigue” Effect

Iron Bioavailability for Mild Anemia

Benefit-Modifying Factors

Potential Risks & Side Effects

High 🟥 🟥 🟥

Heavy-Metal and Mycotoxin Contamination from Unpurified Product

Medium 🟥 🟥

Gastrointestinal Upset

Low 🟥

Allergic and Hypersensitivity Reactions

Increased Iron and Uric Acid Levels

Theoretical Risk of Hormonal Modulation in Hormone-Sensitive Conditions ⚠️ Conflicted

Speculative 🟨

Drug-Metabolism Alterations via Fulvic-Acid Effects on CYP Enzymes

Long-Term Mineral Imbalance with Chronic High-Dose Use

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion